Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 1:14 AM ET

Pharmaceuticals

Company Overview of Solasia Pharma K.K.

Company Overview

Solasia Pharma K.K. engages in developing, marketing, and importing/exporting oncology products. It focuses on developing and commercializing assets in the oncology/hematology fields. The company also provides SP-01 Sancuso, a transdermal system that delivers the anti-emetic and granisetron into the patient’s bloodstream who cannot swallow medicines due to nausea or mucositis; and SP-02 Darinaparsin, a mitochondrial-targeted agent (organic arsenic) for the treatment of various hematologic and solid cancers. It serves customers in Japan, China, Hong Kong, Macau, Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines, Thailand, and internationally. Solasia Pharm...

3rd Floor

Shiodome Building

1-2-20, Kaigan

Minato-ku

Tokyo,  105-0022

Japan

Founded in 2006

Phone:

81 3 6721 8332

Fax:

81 3 6721 2020

Key Executives for Solasia Pharma K.K.

President and Representative Director
Founder and External Director
Age: 48
Chief Financial Officer
Head of Product Development Division
Head of Business Development Department
Compensation as of Fiscal Year 2015.

Solasia Pharma K.K. Key Developments

Solasia Pharma Signs Licensing Agreement with Meiji Seika Pharma

Meiji Seika Pharma Co. Ltd. and Solasia Pharma, K.K. have entered into a license agreement for the development and commercialization of darinaparsin (intravenous formulation) in Japan. Under the terms of the agreement, Solasia will continue to develop darinaparsin for patients with relapsed and refractory PTCL, conduct Phase II Pan-Asian study and upon completion, seek regulatory approval in Japan. Meiji will then commercialize, distribute and promote darinaparsin for PTCL in Japan. In addition, Meiji also obtained the right to develop and commercialize darinaparsin for indications other than relapsed and refractory PTCL in Japan, the option to manufacture intravenous formulation of darinaparsin and a right of first negotiation relating to the formulations other than the intravenous formulation of darinaparsin. In consideration of the license granted to Meiji, Solasia will receive an initial development payment and, upon successful development, regulatory and sales milestone payments, as well as tiered royalties.

Similar Private Companies By Industry

Company Name Region
Fuji Jinentec Farm Corporation Asia
Ryukakusan Co., Ltd. Asia
Kinyo Pharmaceutical Co.,Ltd Asia
AMO Japan K.K. Asia
TOKUHON Corporation Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Solasia Pharma K.K., please visit www.solasia.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.